Poseida Therapeutics Added to Membership of US Small-Cap Russell 2000® Index

SAN DIEGO, Sept. 18, 2020 /PRNewswire/ — Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced its addition as a member of the US small-cap Russell 2000® Index, effective September 18, 2020, as part of the index’s quarterly initial public offering (IPO) additions.